Yirui Biology: The controlling shareholder and concerted actor collectively reduce their holdings by 2.6366%

Erye Biotechnology announced that its controlling shareholder Erye Investment and concerted parties Yidai Rui and Yikai Rui have completed their reduction of holdings from November 12, 2025 to January 29, 2026, totaling 10.68 million shares, accounting for 2.6366% of the total share capital. Among them, Erye Investment reduced 3.82 million shares through centralized bidding at an average price of 9.85 yuan/share, and reduced 6.23 million shares through block trades at an average price of 8.81 yuan/share; Yidai Rui reduced 38,400 shares through centralized bidding at an average price of 9.85 yuan/share, and reduced 250,000 shares through block trades at an average price of 9.76 yuan/share; Yikai Rui reduced 91,800 shares through centralized bidding at an average price of 9.85 yuan/share, and reduced 250,000 shares through block trades at an average price of 9.76 yuan/share. After the reduction, Erye Investment holds 122 million shares, accounting for 30.1973%; Yidai Rui holds 18.7196 million shares, accounting for 4.6213%; Yikai Rui holds 22.2354 million shares, accounting for 5.4893%; the three parties hold a total of 223 million shares, accounting for 55.1625%.